Company profile
Voyager Therapeutics, Inc.
NASDAQ: VYGR · Healthcare · Biotechnology
#466 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
53DFH 46DQ 74GM 26SS 62
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, disclosure history · ↓ revenue growth (YoY), growth stability
Methodology →Revenue TTM
$36.5M
Rev growth YoY (TTM)
-45.5%
Net income (FY)
-$119.7M
Employees
141
as of 2026-08-13
Market cap
$193.3M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$40.4M$40.4M2025
Net income-$119.7M-$119.7M2025
Operating income-$131.8M-$131.8M2025
Total assets$252.3M$252.3M2025
Liabilities$56.2M$56.2M2025
Equity$196.1M$196.1M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2017
By product
Parkinsonprogram100%
By geography
Not disclosed.
The read
What is Voyager Therapeutics, Inc.’s revenue?
Voyager Therapeutics, Inc. booked $40.4M in FY2025 revenue, contracting 50% year over year — slower than 81% of Healthcare companies we track, at a -296.5% net margin.
Peers · Healthcare
Myomo, Inc.53DEditas Medicine, Inc.45DAlpha Teknova, Inc.58CValeo Pharma Inc.——Enveric Biosciences, Inc.31DBig Tree Group, Inc.——Neighbors
Middlesex →Key facts
CEOAlfred W. Sandrock Jr.
SectorHealthcare
IndustryBiotechnology
HeadquartersLexington, MA
ExchangeNASDAQ: VYGR
Employees141
IPO date2015-11-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.